AksharChem Q2FY27 Results: Net profit turns positive at ₹1,332 lakh
- Net profit for Q2FY27 stood at ₹1,332.16 lakh, reversing a loss of ₹136.90 lakh in Q2FY26
- Revenue from operations grew 79.7% YoY to ₹1,604.82 crore
- Trade receivables increased to ₹9,698.05 lakh from ₹6,240.70 lakh as on March 31, 2026
- Munjal M. Jaykrishna re-appointed as MD & CEO for three years subject to shareholder approval

*this image is generated using AI for illustrative purposes only.
AksharChem (India) Limited reported a net profit of ₹1,332.16 lakh for the quarter ended September 30, 2026 (Q2FY27), marking a significant turnaround from the loss of ₹136.90 lakh recorded in Q2FY26.
The specialty chemicals manufacturer saw robust top-line growth, with revenue from operations rising 79.7% YoY to ₹1,604.82 crore. On a sequential basis, revenue expanded 13.9% from ₹1,408.70 crore in Q1FY27. The Board of Directors approved these unaudited financial results on October 19, 2026, alongside key management appointments.
Financial Performance Highlights
The company’s operational momentum was reflected in its profit before tax (PBT), which stood at ₹1,408.53 lakh in Q2FY27, compared to a PBT loss of ₹140.47 lakh in the corresponding period last year. The half-year figures also showed strong recovery, with H1FY27 PBT at ₹3,003.34 lakh against H1FY26 PBT loss of ₹37.24 lakh.
| Metric | Q2FY27 | Q2FY26 | Change |
|---|---|---|---|
| Revenue from Operations | ₹1,604.82 crore | ₹893.02 crore | +79.7% |
| Profit Before Tax | ₹140.85 crore | -₹14.05 crore | Turnaround |
| Net Profit | ₹133.22 crore | -₹13.69 crore | Turnaround |
| EPS (Basic) | ₹16.58 | -₹1.70 | N/A |
Note: Revenue figures converted from lakhs to crores for readability where applicable in analysis, but source data is in lakhs.
Management Appointments and Governance
In addition to the results, the Board approved the change in designation and re-appointment of Munjal M. Jaykrishna as Managing Director & CEO for a term of three years effective October 19, 2026. This appointment is subject to shareholder approval.
Furthermore, the Board recommended the revision in remuneration for Sachin M. Jaykrishna, Whole Time Director, effective October 19, 2026. His re-appointment as Whole Time Director for a three-year term starting August 2, 2027, was also approved, subject to necessary regulatory and shareholder approvals.
What the Numbers Show
A closer look at the balance sheet reveals a divergence between profit growth and cash flow efficiency. While net profit turned significantly positive, trade receivables surged to ₹9,698.05 lakh as on September 30, 2026, up from ₹6,240.70 lakh as on March 31, 2026. This increase of over ₹3,400 lakh suggests that a substantial portion of the revenue growth has not yet been converted into cash inflows, potentially indicating extended credit periods or collection delays despite the strong sales performance.
Additionally, inventory levels rose to ₹8,571.90 lakh from ₹7,300.95 lakh in the same period, aligning with the higher production volumes required to support the 79.7% YoY revenue jump. The company’s cash position remains lean at ₹16.97 lakh, highlighting a reliance on working capital financing to manage the increased receivables and inventory cycles.
Historical Stock Returns for AksharChem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.78% | +11.45% | +8.57% | +112.85% | +54.97% | 0.0% |
How will AksharChem address the significant gap between surging trade receivables and its lean cash position to mitigate working capital risks in the next quarter?
What specific product segments or export markets drove the 79.7% YoY revenue growth, and is this momentum sustainable given global specialty chemical demand trends?
Will the re-appointment of the Jaykrishna family leadership team lead to a shift in capital allocation strategy, particularly regarding debt reduction versus capacity expansion?


































